

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226560 A1

(51) International Patent Classification:	63/057,767	28 July 2020 (28.07.2020)	US
<i>C07K 16/10</i> (2006.01)	63/090,667	12 October 2020 (12.10.2020)	US
<i>A61K 39/395</i> (2006.01)	63/113,450	13 November 2020 (13.11.2020)	US
<i>A61P 31/14</i> (2006.01)	63/153,784	25 February 2021 (25.02.2021)	US
(21) International Application Number:	63/170,368	02 April 2021 (02.04.2021)	US
	PCT/US2021/031442		
(22) International Filing Date:			
	07 May 2021 (07.05.2021)		
(25) Filing Language:	English		
(26) Publication Language:	English		
(30) Priority Data:			
63/022,392	08 May 2020 (08.05.2020)	US	
63/024,372	13 May 2020 (13.05.2020)	US	
63/027,814	20 May 2020 (20.05.2020)	US	
63/029,338	22 May 2020 (22.05.2020)	US	
63/031,286	28 May 2020 (28.05.2020)	US	
63/033,045	01 June 2020 (01.06.2020)	US	
63/036,683	09 June 2020 (09.06.2020)	US	
63/039,939	16 June 2020 (16.06.2020)	US	
63/046,465	30 June 2020 (30.06.2020)	US	
(71) Applicants:	VIR BIOTECHNOLOGY, INC. [US/US]; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US). HUMABS BIOMED SA [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH).		
(72) Inventors; and			
(71) Applicants:	CORTI, Davide [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH). PIZZUTO, Matteo [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH). PINTO, Do- ra [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH). BELTRAMELLO, Martina [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH). DE MARCO, Anna [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH). CAMERONI, Elisabetta [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH). SNELL, Gyorgy [US/US]; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US). CZUDNO- CHOWSKI, Nadine [US/US]; 499 Illinois Street, Suite		

(54) Title: ANTIBODIES AGAINST SARS-COV-2




FIG. 53

(57) Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of potentially neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode antibodies and antigen-binding fragments, vectors, host cells, and related compositions and uses, including for preventing, treating, and diagnosing an infection by SARS-CoV-2 or another coronavirus.

[Continued on next page]

500, San Francisco, California 94158 (US). **HAVENAR, Colin** [US/US]; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US). **LEMPP, Florian** [US/US]; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US). **TELENTI, Amalio** [US/US]; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US).

(74) **Agent: MORGAN, John, A.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))